Clinical Edge Journal Scan

Key clinical point: The immune checkpoint protein B7-H3 expression correlated positively with androgen receptor expression and was associated with biochemical and clinical recurrence in prostate cancer.

Major finding: Researchers identified B7-H3 positivity in 15% of prostate cancer patients in a Spanish cohort and 38% of patients in a Norwegian cohort. B7-H3 expression was significantly associated with biochemical recurrence in the Spanish cohort (P = .003) and with clinical recurrence in the Norwegian cohort (P = .005).

Study details: The data come from an immunohistochemistry analysis of tissue samples from a total of 327 prostate adenocarcinoma patients who underwent radical prostatectomy; 120 from Spain and 206 from Norway.

Disclosures: The study was funded by the Instituto de Salud Carlos III, the Ministerio de Economía y Competitividad, the Research Council of Norway, Marie Skłodowska-Curie Actions, Radiumhospitalets legater, Norway, and UNIFOR-FRIMED legater, Norway. The researchers had no financial conflicts to disclose.

Source: Nunes-Xavier CE et al. Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.

Key clinical point: The immune checkpoint protein B7-H3 expression correlated positively with androgen receptor expression and was associated with biochemical and clinical recurrence in prostate cancer.

Major finding: Researchers identified B7-H3 positivity in 15% of prostate cancer patients in a Spanish cohort and 38% of patients in a Norwegian cohort. B7-H3 expression was significantly associated with biochemical recurrence in the Spanish cohort (P = .003) and with clinical recurrence in the Norwegian cohort (P = .005).

Study details: The data come from an immunohistochemistry analysis of tissue samples from a total of 327 prostate adenocarcinoma patients who underwent radical prostatectomy; 120 from Spain and 206 from Norway.

Disclosures: The study was funded by the Instituto de Salud Carlos III, the Ministerio de Economía y Competitividad, the Research Council of Norway, Marie Skłodowska-Curie Actions, Radiumhospitalets legater, Norway, and UNIFOR-FRIMED legater, Norway. The researchers had no financial conflicts to disclose.

Source: Nunes-Xavier CE et al. Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.

Key clinical point: The immune checkpoint protein B7-H3 expression correlated positively with androgen receptor expression and was associated with biochemical and clinical recurrence in prostate cancer.

Major finding: Researchers identified B7-H3 positivity in 15% of prostate cancer patients in a Spanish cohort and 38% of patients in a Norwegian cohort. B7-H3 expression was significantly associated with biochemical recurrence in the Spanish cohort (P = .003) and with clinical recurrence in the Norwegian cohort (P = .005).

Study details: The data come from an immunohistochemistry analysis of tissue samples from a total of 327 prostate adenocarcinoma patients who underwent radical prostatectomy; 120 from Spain and 206 from Norway.

Disclosures: The study was funded by the Instituto de Salud Carlos III, the Ministerio de Economía y Competitividad, the Research Council of Norway, Marie Skłodowska-Curie Actions, Radiumhospitalets legater, Norway, and UNIFOR-FRIMED legater, Norway. The researchers had no financial conflicts to disclose.

Source: Nunes-Xavier CE et al. Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.

Key clinical point: At 6 months after robot-assisted radical prostatectomy, functional outcomes, but not postoperative complications, were associated with poor scores on quality-of-life assessments.

Major finding: Functional outcomes of urinary incontinence (UI), erectile dysfunction (ED), and urinary complaints (UC) were not significantly associated with post-operative health-related quality of life, but postoperative complications were significantly associated with a slight increase in UC (P < 0.001).

Study details: The data come from an analysis of 528 prostate cancer patients who underwent robot-assisted radical prostatectomy with or without pelvic node dissection between 2012 and 2020.  Patients completed questionnaires about health-related quality of life and functional outcomes.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Hagens MJ et al. J Robotic Surg. 2021 Jun 12. doi: /10.1007/s11701-021-01266-9.

Key clinical point: At 6 months after robot-assisted radical prostatectomy, functional outcomes, but not postoperative complications, were associated with poor scores on quality-of-life assessments.

Major finding: Functional outcomes of urinary incontinence (UI), erectile dysfunction (ED), and urinary complaints (UC) were not significantly associated with post-operative health-related quality of life, but postoperative complications were significantly associated with a slight increase in UC (P < 0.001).

Study details: The data come from an analysis of 528 prostate cancer patients who underwent robot-assisted radical prostatectomy with or without pelvic node dissection between 2012 and 2020.  Patients completed questionnaires about health-related quality of life and functional outcomes.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Hagens MJ et al. J Robotic Surg. 2021 Jun 12. doi: /10.1007/s11701-021-01266-9.

Key clinical point: At 6 months after robot-assisted radical prostatectomy, functional outcomes, but not postoperative complications, were associated with poor scores on quality-of-life assessments.

Major finding: Functional outcomes of urinary incontinence (UI), erectile dysfunction (ED), and urinary complaints (UC) were not significantly associated with post-operative health-related quality of life, but postoperative complications were significantly associated with a slight increase in UC (P < 0.001).

Study details: The data come from an analysis of 528 prostate cancer patients who underwent robot-assisted radical prostatectomy with or without pelvic node dissection between 2012 and 2020.  Patients completed questionnaires about health-related quality of life and functional outcomes.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Hagens MJ et al. J Robotic Surg. 2021 Jun 12. doi: /10.1007/s11701-021-01266-9.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: Gleason scores within grade group 4 prostate cancer were associated with biochemical recurrence, but not cancer-specific mortality or all-cause mortality.

Major finding: Gleason score (GS) 5 + 3 was associated with significantly higher rates of GS upgrading in radical prostatectomy (RP) specimens than either GS 3 + 5 or GS 4 + 4.

Study details: The data come from a retrospective review of 1,791 adults with grade 4 prostate cancer, including 190 with Gleason score (GS) 3 + 5; 1,557 with GS 4 + 4; and 44 with GS 5 + 3).

Disclosures: The study was funded in part by the Medical University of Vienna. The researchers had no financial conflicts to disclose.

Source: Mori K et al. Ann Surg Oncol. 2021 Jun 11. doi: 10.1245/s10434-021-10257-x.

Key clinical point: Gleason scores within grade group 4 prostate cancer were associated with biochemical recurrence, but not cancer-specific mortality or all-cause mortality.

Major finding: Gleason score (GS) 5 + 3 was associated with significantly higher rates of GS upgrading in radical prostatectomy (RP) specimens than either GS 3 + 5 or GS 4 + 4.

Study details: The data come from a retrospective review of 1,791 adults with grade 4 prostate cancer, including 190 with Gleason score (GS) 3 + 5; 1,557 with GS 4 + 4; and 44 with GS 5 + 3).

Disclosures: The study was funded in part by the Medical University of Vienna. The researchers had no financial conflicts to disclose.

Source: Mori K et al. Ann Surg Oncol. 2021 Jun 11. doi: 10.1245/s10434-021-10257-x.

Key clinical point: Gleason scores within grade group 4 prostate cancer were associated with biochemical recurrence, but not cancer-specific mortality or all-cause mortality.

Major finding: Gleason score (GS) 5 + 3 was associated with significantly higher rates of GS upgrading in radical prostatectomy (RP) specimens than either GS 3 + 5 or GS 4 + 4.

Study details: The data come from a retrospective review of 1,791 adults with grade 4 prostate cancer, including 190 with Gleason score (GS) 3 + 5; 1,557 with GS 4 + 4; and 44 with GS 5 + 3).

Disclosures: The study was funded in part by the Medical University of Vienna. The researchers had no financial conflicts to disclose.

Source: Mori K et al. Ann Surg Oncol. 2021 Jun 11. doi: 10.1245/s10434-021-10257-x.

Key clinical point: The Briganti 2019 nomogram accurately predicted lymph node invasion in adults with high-risk, clinically localized prostate cancer.

Major finding: The area under the curve for the Briganti 2019 was 0.71. At a cutoff of 7%, sensitivity, specificity, and negative predictive values were 94.7%, 32.0%a, and 98.8%, respectively.

Study details: The data come from a review of 278 adults with prostate cancer who underwent radical prostatectomy and extended pelvic lymph node dissection. Patients were rated using the Briganti 2019 nomogram; researchers used the area under the curve of the receiver operating characteristic analysis to quantify accuracy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Fukagawa E et al. Int J Clin Oncol. 2021 Jun 12. doi: 10.1007/s10147-021-01954-4. 

Key clinical point: The Briganti 2019 nomogram accurately predicted lymph node invasion in adults with high-risk, clinically localized prostate cancer.

Major finding: The area under the curve for the Briganti 2019 was 0.71. At a cutoff of 7%, sensitivity, specificity, and negative predictive values were 94.7%, 32.0%a, and 98.8%, respectively.

Study details: The data come from a review of 278 adults with prostate cancer who underwent radical prostatectomy and extended pelvic lymph node dissection. Patients were rated using the Briganti 2019 nomogram; researchers used the area under the curve of the receiver operating characteristic analysis to quantify accuracy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Fukagawa E et al. Int J Clin Oncol. 2021 Jun 12. doi: 10.1007/s10147-021-01954-4. 

Key clinical point: The Briganti 2019 nomogram accurately predicted lymph node invasion in adults with high-risk, clinically localized prostate cancer.

Major finding: The area under the curve for the Briganti 2019 was 0.71. At a cutoff of 7%, sensitivity, specificity, and negative predictive values were 94.7%, 32.0%a, and 98.8%, respectively.

Study details: The data come from a review of 278 adults with prostate cancer who underwent radical prostatectomy and extended pelvic lymph node dissection. Patients were rated using the Briganti 2019 nomogram; researchers used the area under the curve of the receiver operating characteristic analysis to quantify accuracy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Fukagawa E et al. Int J Clin Oncol. 2021 Jun 12. doi: 10.1007/s10147-021-01954-4. 

Treatment of prostate cancer presents significant challenges with respect to balancing efficacy and side effects of treatments. Thus, quality of life endpoints are included in studies of patients with prostate cancer to better understand and counsel patients with this heterogenous disease. In the 3 studies discussed here, functional or quality of life outcomes were included in the analyses.

            In the first study, Hagens et al evaluated the effects of postoperative complications of robot-assisted radical prostatectomy on the health-related quality of life (HRQoL) as measured via surveys and assessment of functional outcomes. While no significant association between HRQoL at 6 months and complications postoperatively were identified, there was an association between functional outcomes and HRQoL at 6 months identified. Thus, future studies designed to identify more optimal patient selection or improved surgical techniques may benefit patients.

            Studies have suggested that androgen deprivation therapy (ADT) may be associated with decreased cognitive function. However, other studies suggested that ADT via luteinizing hormone releasing hormone (LHRH) agonists or antagonists may actually have a protective effect against decreased cognitive function due to low gonadotropin exposure. Andela et al conducted a systematic review based on this hypothesis. Of the 31 studies included in the review, 16 demonstrated that ADT was not associated with decreased cognitive function, while 11 studies did support this association and 4 studies were inconclusive. Therefore, no definitive conclusions can be made based on this review, and further randomized studies are needed.

            Radiation to the prostate may affect the rectum with sometimes significant effects. Hydrogel spacers injected between the prostate and rectum have been evaluated in patients with conventional radiation previously with evidence of benefit, but the benefits for patients undergoing stereotactic body radiotherapy (SBRT) are unknown. Ogita et al conducted a phase II single-arm study designed to evaluate the effects of a hydrogel spacer on gastrointestinal toxicity within 3 months of SBRT. Physician-assessed toxicity was not reduced, but patient reported toxicity was improved compared with historical controls. While this study does not support routine use in the setting of prostate SBRT, it does suggest that future larger randomized studies are worth consideration.

Treatment of prostate cancer presents significant challenges with respect to balancing efficacy and side effects of treatments. Thus, quality of life endpoints are included in studies of patients with prostate cancer to better understand and counsel patients with this heterogenous disease. In the 3 studies discussed here, functional or quality of life outcomes were included in the analyses.

            In the first study, Hagens et al evaluated the effects of postoperative complications of robot-assisted radical prostatectomy on the health-related quality of life (HRQoL) as measured via surveys and assessment of functional outcomes. While no significant association between HRQoL at 6 months and complications postoperatively were identified, there was an association between functional outcomes and HRQoL at 6 months identified. Thus, future studies designed to identify more optimal patient selection or improved surgical techniques may benefit patients.

            Studies have suggested that androgen deprivation therapy (ADT) may be associated with decreased cognitive function. However, other studies suggested that ADT via luteinizing hormone releasing hormone (LHRH) agonists or antagonists may actually have a protective effect against decreased cognitive function due to low gonadotropin exposure. Andela et al conducted a systematic review based on this hypothesis. Of the 31 studies included in the review, 16 demonstrated that ADT was not associated with decreased cognitive function, while 11 studies did support this association and 4 studies were inconclusive. Therefore, no definitive conclusions can be made based on this review, and further randomized studies are needed.

            Radiation to the prostate may affect the rectum with sometimes significant effects. Hydrogel spacers injected between the prostate and rectum have been evaluated in patients with conventional radiation previously with evidence of benefit, but the benefits for patients undergoing stereotactic body radiotherapy (SBRT) are unknown. Ogita et al conducted a phase II single-arm study designed to evaluate the effects of a hydrogel spacer on gastrointestinal toxicity within 3 months of SBRT. Physician-assessed toxicity was not reduced, but patient reported toxicity was improved compared with historical controls. While this study does not support routine use in the setting of prostate SBRT, it does suggest that future larger randomized studies are worth consideration.

Treatment of prostate cancer presents significant challenges with respect to balancing efficacy and side effects of treatments. Thus, quality of life endpoints are included in studies of patients with prostate cancer to better understand and counsel patients with this heterogenous disease. In the 3 studies discussed here, functional or quality of life outcomes were included in the analyses.

            In the first study, Hagens et al evaluated the effects of postoperative complications of robot-assisted radical prostatectomy on the health-related quality of life (HRQoL) as measured via surveys and assessment of functional outcomes. While no significant association between HRQoL at 6 months and complications postoperatively were identified, there was an association between functional outcomes and HRQoL at 6 months identified. Thus, future studies designed to identify more optimal patient selection or improved surgical techniques may benefit patients.

            Studies have suggested that androgen deprivation therapy (ADT) may be associated with decreased cognitive function. However, other studies suggested that ADT via luteinizing hormone releasing hormone (LHRH) agonists or antagonists may actually have a protective effect against decreased cognitive function due to low gonadotropin exposure. Andela et al conducted a systematic review based on this hypothesis. Of the 31 studies included in the review, 16 demonstrated that ADT was not associated with decreased cognitive function, while 11 studies did support this association and 4 studies were inconclusive. Therefore, no definitive conclusions can be made based on this review, and further randomized studies are needed.

            Radiation to the prostate may affect the rectum with sometimes significant effects. Hydrogel spacers injected between the prostate and rectum have been evaluated in patients with conventional radiation previously with evidence of benefit, but the benefits for patients undergoing stereotactic body radiotherapy (SBRT) are unknown. Ogita et al conducted a phase II single-arm study designed to evaluate the effects of a hydrogel spacer on gastrointestinal toxicity within 3 months of SBRT. Physician-assessed toxicity was not reduced, but patient reported toxicity was improved compared with historical controls. While this study does not support routine use in the setting of prostate SBRT, it does suggest that future larger randomized studies are worth consideration.

Key clinical point: A high number of young women with breast cancer receive guideline-concordant care (GCC).

Major finding: GCC was given to 81.7% of the patients. Patients with stage III vs. stage I or II disease (93.4% vs. 88.4%) received GCC more frequently in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive or HR-negative/HER-positive subtypes. In women with HR-negative/HER2-negative or HR-positive/HER2-negative tumors, a higher proportion of patients with stage II vs stage I or III disease received GCC (91.8% vs. 83.7%).

Study details: A retrospective study of 1,295 young women with invasive breast cancer diagnosed in 2013.

Disclosures: This study was supported by the National Cancer Institute. Dr. AW Kurian received research funding from Myriad Genetics and served on the board of directors of a patient advocacy group outside this work. The other authors reported no conflicts of interest.

Source: White DP. Cancer. 2021 Jun 1. doi: 10.1002/cncr.33652.

Key clinical point: A high number of young women with breast cancer receive guideline-concordant care (GCC).

Major finding: GCC was given to 81.7% of the patients. Patients with stage III vs. stage I or II disease (93.4% vs. 88.4%) received GCC more frequently in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive or HR-negative/HER-positive subtypes. In women with HR-negative/HER2-negative or HR-positive/HER2-negative tumors, a higher proportion of patients with stage II vs stage I or III disease received GCC (91.8% vs. 83.7%).

Study details: A retrospective study of 1,295 young women with invasive breast cancer diagnosed in 2013.

Disclosures: This study was supported by the National Cancer Institute. Dr. AW Kurian received research funding from Myriad Genetics and served on the board of directors of a patient advocacy group outside this work. The other authors reported no conflicts of interest.

Source: White DP. Cancer. 2021 Jun 1. doi: 10.1002/cncr.33652.

Key clinical point: A high number of young women with breast cancer receive guideline-concordant care (GCC).

Major finding: GCC was given to 81.7% of the patients. Patients with stage III vs. stage I or II disease (93.4% vs. 88.4%) received GCC more frequently in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive or HR-negative/HER-positive subtypes. In women with HR-negative/HER2-negative or HR-positive/HER2-negative tumors, a higher proportion of patients with stage II vs stage I or III disease received GCC (91.8% vs. 83.7%).

Study details: A retrospective study of 1,295 young women with invasive breast cancer diagnosed in 2013.

Disclosures: This study was supported by the National Cancer Institute. Dr. AW Kurian received research funding from Myriad Genetics and served on the board of directors of a patient advocacy group outside this work. The other authors reported no conflicts of interest.

Source: White DP. Cancer. 2021 Jun 1. doi: 10.1002/cncr.33652.

Key clinical point: High or medium human trophoblast cell-surface antigen-2 (Trop-2) expression is associated with numerically higher survival with sacituzumab govitecan in patients with metastatic triple-negative breast cancer (TNBC).

Major finding: The median progression-free survival in the sacituzumab govitecan group was 6.9, 5.6, and 2.7 months in the patients with high, medium, and low Trop-2 H-scores, respectively. The median overall survival with sacituzumab govitecan was 14.2, 14.9, and 9.3 months in patients with high, medium, and low Trop-2 scores, respectively. The germline BRCA1/2 mutation status did not affect the outcomes in the sacituzumab govitecan vs. chemotherapy group.

Study details: A prespecified, exploratory biomarker analysis from the ASCENT trial evaluated the association between tumor Trop-2 expression and germline BRCA1/2 mutation status with clinical outcomes in patients with metastatic TNBC. The patients were randomly assigned to sacituzumab govitecan or chemotherapy.

Disclosures: This study was sponsored by Immunomedics, Inc. The authors received consulting/advisory fees, research funding, travel/accommodations/expenses, speaker fees, nonfinancial support, and/or declared intellectual property rights, patents, and royalties from various companies/organizations. Dr. K Kalinsky reported spouse employment at Array Biopharma. The authors disclosed no other potential conflicts of interest.

Source: Bardia A et al. Ann Oncol. 2021 Jun 8. doi: 10.1016/j.annonc.2021.06.002.

Key clinical point: High or medium human trophoblast cell-surface antigen-2 (Trop-2) expression is associated with numerically higher survival with sacituzumab govitecan in patients with metastatic triple-negative breast cancer (TNBC).

Major finding: The median progression-free survival in the sacituzumab govitecan group was 6.9, 5.6, and 2.7 months in the patients with high, medium, and low Trop-2 H-scores, respectively. The median overall survival with sacituzumab govitecan was 14.2, 14.9, and 9.3 months in patients with high, medium, and low Trop-2 scores, respectively. The germline BRCA1/2 mutation status did not affect the outcomes in the sacituzumab govitecan vs. chemotherapy group.

Study details: A prespecified, exploratory biomarker analysis from the ASCENT trial evaluated the association between tumor Trop-2 expression and germline BRCA1/2 mutation status with clinical outcomes in patients with metastatic TNBC. The patients were randomly assigned to sacituzumab govitecan or chemotherapy.

Disclosures: This study was sponsored by Immunomedics, Inc. The authors received consulting/advisory fees, research funding, travel/accommodations/expenses, speaker fees, nonfinancial support, and/or declared intellectual property rights, patents, and royalties from various companies/organizations. Dr. K Kalinsky reported spouse employment at Array Biopharma. The authors disclosed no other potential conflicts of interest.

Source: Bardia A et al. Ann Oncol. 2021 Jun 8. doi: 10.1016/j.annonc.2021.06.002.

Key clinical point: High or medium human trophoblast cell-surface antigen-2 (Trop-2) expression is associated with numerically higher survival with sacituzumab govitecan in patients with metastatic triple-negative breast cancer (TNBC).

Major finding: The median progression-free survival in the sacituzumab govitecan group was 6.9, 5.6, and 2.7 months in the patients with high, medium, and low Trop-2 H-scores, respectively. The median overall survival with sacituzumab govitecan was 14.2, 14.9, and 9.3 months in patients with high, medium, and low Trop-2 scores, respectively. The germline BRCA1/2 mutation status did not affect the outcomes in the sacituzumab govitecan vs. chemotherapy group.

Study details: A prespecified, exploratory biomarker analysis from the ASCENT trial evaluated the association between tumor Trop-2 expression and germline BRCA1/2 mutation status with clinical outcomes in patients with metastatic TNBC. The patients were randomly assigned to sacituzumab govitecan or chemotherapy.

Disclosures: This study was sponsored by Immunomedics, Inc. The authors received consulting/advisory fees, research funding, travel/accommodations/expenses, speaker fees, nonfinancial support, and/or declared intellectual property rights, patents, and royalties from various companies/organizations. Dr. K Kalinsky reported spouse employment at Array Biopharma. The authors disclosed no other potential conflicts of interest.

Source: Bardia A et al. Ann Oncol. 2021 Jun 8. doi: 10.1016/j.annonc.2021.06.002.

Key clinical point: Olaparib monotherapy is effective in germline BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer in a real-world setting.

Major finding: The median progression-free survival was 8.11 months, and the clinical response rate was 48.6%. The grade 3 or higher treatment-related adverse event rate was 25.4%. There were no new safety signals.

Study details: An interim analysis of an open-label, single-arm, phase 3b LUCY trial including 252 previously treated patients with HER2-negative metastatic breast cancer with a germline BRCA mutation who received olaparib.

Disclosures: The study was funded by AstraZeneca. Dr. S McCutcheon was an employee and stockholder of AstraZeneca LP. Dr. J Bennett and Dr. G Walker were contractors for AstraZeneca LP. The authors received consulting/speaker fees or research support from various sources.

Source: Gelmon KA et al. Eur J Cancer. 2021 Jun 1. doi: 10.1016/j.ejca.2021.03.029.

Key clinical point: Olaparib monotherapy is effective in germline BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer in a real-world setting.

Major finding: The median progression-free survival was 8.11 months, and the clinical response rate was 48.6%. The grade 3 or higher treatment-related adverse event rate was 25.4%. There were no new safety signals.

Study details: An interim analysis of an open-label, single-arm, phase 3b LUCY trial including 252 previously treated patients with HER2-negative metastatic breast cancer with a germline BRCA mutation who received olaparib.

Disclosures: The study was funded by AstraZeneca. Dr. S McCutcheon was an employee and stockholder of AstraZeneca LP. Dr. J Bennett and Dr. G Walker were contractors for AstraZeneca LP. The authors received consulting/speaker fees or research support from various sources.

Source: Gelmon KA et al. Eur J Cancer. 2021 Jun 1. doi: 10.1016/j.ejca.2021.03.029.

Key clinical point: Olaparib monotherapy is effective in germline BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer in a real-world setting.

Major finding: The median progression-free survival was 8.11 months, and the clinical response rate was 48.6%. The grade 3 or higher treatment-related adverse event rate was 25.4%. There were no new safety signals.

Study details: An interim analysis of an open-label, single-arm, phase 3b LUCY trial including 252 previously treated patients with HER2-negative metastatic breast cancer with a germline BRCA mutation who received olaparib.

Disclosures: The study was funded by AstraZeneca. Dr. S McCutcheon was an employee and stockholder of AstraZeneca LP. Dr. J Bennett and Dr. G Walker were contractors for AstraZeneca LP. The authors received consulting/speaker fees or research support from various sources.

Source: Gelmon KA et al. Eur J Cancer. 2021 Jun 1. doi: 10.1016/j.ejca.2021.03.029.